This not only supports healthcare professionals (HCPs) to identify poor responders and to individualize treatment to optimize growth outcomes, but also allows patients with growth disorders the opportunity to see the expected effect of their r-hGH treatment. This evidence concerns the gene GH1 and hereditary endocrine growth disease.